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Non-small cell lung cancer (NSCLC) remains to be primary reason of 
tumor deaths in the past few decades. The mortality of this malignancy 
could be reduced by developing new prognostic biomarkers and discov-
ering novel therapeutic biological target. Here, we studied the mRNA 
expression of FOX gene family and UBE2C in different types of cancer 
compared with normal tissue through ONCOMINE differential analysis. 
CCLE analysis was mined to explore the expression profiles of target 
genes in different tumor cells. GEPIA was used to discover the expression 
of target genes in different subtypes and the correlations with lung cancer 
stage. The prognostic values of FOXM1 and UBE2C were further inves-
tigated through Kaplan-Meier plotter analysis. It showed that FOXA1, 
FOXD1 and FOXM1 were dramatically high expressed in NSCLC com-
paring with normal lung tissues. Besides, the expression of FOXM1 was 
signi cantly associated with UBE2C. Furthermore, the overexpression of 
FOXM1 and UBE2C were correlated to shorter survival in lung adenocar-
cinoma (LAC) instead of lung squamous cell carcinoma (LSCC). Hence, 
we could draw a conclusion that FOXM1 and UBE2C are distinguished 
biomarkers and crucial prognostic indicators for lung adenocarcinoma 
patients.
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1. Introduction
C
arcinoma of the lungs is the leading cause of 
tumor mortality around the world and about 
80–85% of lung cancers are NSCLC consisted 
of large-cell carcinoma, lung adenocarcinoma (LAC) and 
lung squamous cell carcinoma (LSCC).[1] It is notable that 
the 5-year survival rate has remained at ~17% over previ-
ous decades.[2] Moreover, as the symptoms associated with 
lung cancer are often non-specific, it is frequently diag-
nosed in the advanced stages.[3] Therefore, it is required to 
develop new prognostic biomarkers and discovering novel 
therapeutic biological target.
The human FOX (Forkhead box) gene family is a 
key regulatory transcription factor family, composed of 
19 subgroups and 50 members, named from FOXA1 to 
FOXS1.[4] Fox family genes control the expression of oth-
er genes by regulating the activity of transcription factors, 
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regulating the growth, differentiation, apoptosis, prolif-
eration, migration, invasion and angiogenesis of tumor 
cells.[5] FOXM1, as one of the most widely investigated 
gene from the FOX gene family, is a transcription factor 
overexpressed in various of tumor cells such as breast 
carcinoma, ovarian cancer, gastric and other cancers.[6,7] It 
plays a vital role on stimulating cell proliferation through 
cell cycle progression and transcriptional regulation of 
important genes for G1/S and G2/M phase transition and 
M phase progression.[8] It is reported that the poor progno-
sis in glioblastoma patients was related to FOXM1 gene 
overexpression.[9] Therefore, FOXM1 is likely to be an 
important prognostic biomarker in NSCLC patients.
Recently, it was shown that UBE2C expression was 
transcriptionally regulates by FOXM1 in esophageal squa-
mous cell cancer and the regulation may be a widespread 
phenomenon in human tumor.[10] UBE2C/UBCH10, as an 
E2 ubiquitin-conjugating enzyme, plays an important role 
on regulation mitosis and cell cycle.[11] It has been indi-
cated that UBE2C was overexpressed in a range of tumor 
and associated with poor prognosis in several types of 
cancer including ESCC and colorectal cancer.[12,13] These 
 ndings revealed that UBE2C is likely to be oncogene in 
lung cancer. 
In the current study, we examined the expression of 
FOX gene family and UBE2C in different types of cancer 
compared with normal tissue, with purpose of determining 
the expression levels of FOXM1 and UBE2C and the cor-
relations between FOXM1 and UBE2C, along with their 
corresponding prognostic signi cance in NSCLC.
2. Material and Methods
2.1 ONCOMINE Databases
ONCOMINE database (www.oncomine.org), an open and 
convenient online cancer microarray database, integrated 
715 datasets and 86,733 samples. It is a powerful web 
application through which mRNA expression levels of 
FOXM1 and UBE2C in a large volume of cancer types, 
subtypes, and experiments were explored. Signi cant cor-
relations between gene and cancer can be show in a spe-
cial  gure. Co-expressed disease-related genes can also be 
mined through this database.
2.2 CCLE (Cancer Cell Line Encyclopedia) Anal-
ysis
The Cancer Cell Line Encyclopedia (CCLE) (https://por-
tals.broadinstitute.org/ccle/), as a newly developed web-
site, provides analysis tools including integrative genom-
ics viewer (IGV), differential expression analysis, gene 
co-expression, gene set enrichment analysis (GSEA). The 
CCLE enables public access to genomic data, analysis and 
visualization for about 1000 cell lines.
2.3 GEPIA (Gene Expression Profling Interactive 
Analysis)
Gene expression profiling interactive analysis (http://
gepia.cancer-pku.cn/), an open interactive web server, 
provides customized functions such as tumor/normal dif-
ferential expression analysis, pro ling plotting according 
to cancer types or pathological stages, patient survival 
analysis and so on. This is a time-saving and intuitive tool 
integrated approximately 9,736 tumors and 8,587 normal 
samples from the TCGA and the GTEx projects.[14]
2.4 The Kaplan-Meier Plotter
The Kaplan Meier plotter (http:// kmplot.com/analysis/), 
an online database including 2,437 lung cancer patients 
and 54,675 genes from GEO, EGA and TCGA, is capa-
ble to assess relapse free and overall survival[15]. Patients 
were split into two cohorts by gene expression and were 
compared by a Kaplan-Meier survival plot, through which 
prognostic values of FOXM1 and UBE2C expressions 
were estimated. The hazard ratio with 95% con dence in-
tervals and logrank P value are calculated. The difference 
was statistically signi cant in P-value < 0.01.
3. Results
3.1 FOXM1, FOXA1, FOXD1 and UBE2C Were 
Signifcantly Overexpressed In Lung Cancer
To examine the transcription level of all the members in 
FOX gene family in lung cancer, we performed concept 
analysis through ONCOMINE databases, which revealed 
that FOXA1, FOXD1, FOXM1, FOXK2 and FOXC1 
were overexpressed in lung cancer in a database with 203 
samples. FOXA1 transcripts were 7.19 fold elevated in 
lung adenocarcinoma comparing with normal lung tissue 
(p=2.55e-7). FOXD1 transcripts were 2.22 fold elevated 
in comparing with normal lung tissue (p=0.003). FOXM1, 
FOXK2 and FOXC1 were also distinctively overex-
pressed in lung cancer contrasting with normal lung in a 
database with 203 samples. (Figure 1A)
Additionally, the expressions of FOXA1, FOXD1, 
FOXM1, FOXK2, FOXC1 and UBE2C in a range of 
cancers were further explored through ONCOMINE 
analysis. It was found out that FOXM1 and UBE2C were 
significantly high expressed in a variety including brain 
and CNS cancer, breast cancer, colorectal cancer, sarcoma 
and especially lung cancer. FOXA1 and FOXD1 were 
comparatively high expressed in lung cancer. However, 
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FOXK2 and FOXC1 had no signi cant different expres-
sion in lung cancer. (Figure 1B)
1A: The transcription level of all the members in FOX 
gene family in lung cancer
Notes: The top highly expressed FOX family members in lung cancer in 
a research including 203 samples were showed in this  gure.
1B: The expression level of FOXA1, FOXD1, FOXM1, 
FOXK2 and FOXC1 in diverse cancers versus normal 
tissue
Notes: Overexpressed was in red, while low expressed was in blue. The 
number represents the number of studies meet the threshold in the ON-
COMINE database.
Figure 1. The overexpression of UBE2C was distinctly 
associated with FOXM1 expression
Since it was found out that FOXM1 was distinctively 
overexpressed in lung carcinoma and a variety of other 
cancers, we next carried out further exploration on the 
co-expression gene of FOXM1 through ONCOMINE da-
tabase, which indicated that the expression of UBE2C was 
significantly related to FOXM1(r=0.789). (Figure 2A) 
The result was demonstrated through CCLE analysis that 
FOXM1 and UBE2C were signi cantly high expressed in 
lung carcinoma cell comparing with other tumor cell lines. 
(Figure 2B)
2A: The co-expression analysis of FOXM1 and UBE2C
Notes: In ONCOMINE database, the co-expression genes of FOXM1 in 
lung cancer within a database including 73 samples were shown in this 
 gure.
2B: The expression level of FOXM1 and UBE2C in a 
variety of cancer cell lines through CCLE analysis
Notes: FOXM1 was the 3rd highest overexpressed in lung cell line 
behind meningioma and T-cell-ALL, while UBE2C was 2nd highest 
overexpressed in lung cancer cell behind urinary tract in different types 
of cancer cell lines.
Figure 2. The expression level of FOXA1, FOXD1, 
FOXM1 and UBE2C in lung adenocarcinoma and lung 
squamous carcinoma
We compared the expression level of FOXA1, FOXD1, 
FOXM1 and UBE2C in lung adenocarcinoma and lung 
squamous carcinoma through GEPIA dataset, which 
indicated that FOXA1 was overexpressed in lung ade-
nocarcinoma (LUAD) instead of lung squamous carci-
noma(LUSC), whereas FOXD1 was high expressed in 
squamous cell lung carcinoma(LUSC) tissues instead of 
LUAD. The expression level of FOXM1 and UBE2C 
were signi cantly high in both LUAD and LUSC. (Figure 
3A, Figure 3B) 
DOI: https://doi.org/10.30564/jams.v2i2.611
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3A: The chromosomal distribution of over-red or un-
der-green expressed genes was plotted through GEPIA 
analysis
3B: The expression of FOXA1, FOXD1, FOXM1 and 
UBE2C in LUAD and LUSC was plotted by Boxplot 
through GEPIA analysis
Figure 3. The expression level of FOXA1, FOXD1, 
FOXM1 and UBE2C in lung adenocarcinoma and lung 
squamous carcinoma
3.2 Correlations between FOXA1, FOXD1, 
FOXM1 and UBE2C Expression and Tumor 
Stage in Lung Cancer Patients
We also further analyzed the expression of FOXA1, 
FOXD1, FOXM1 and UBE2C with tumor stage for lung 
adenocarcinoma (LAC) and squamous cell lung carcinoma 
(LSCC). It was found out that FOXM1 and UBE2C were 
distinctively varied from different stages in all lung cancer. 
The later was the clinical stage, the higher were FOXM1 
and UBE2C expression levels. However, FOXA1 and 
FOXD1 did not signi cantly differ (P>0.05). (Figure 4)
Figure 4. Association of FOXA1, FOXD1, FOXM1 and 
UBE2C expression with tumor stage in LC patients
Notes: In GEPIA analysis, association of the target gene in lung adeno-
carcinoma (LAC) and squamous cell lung carcinoma (LSCC) stage was 
achieved.
3.3 The Prognostic Values of mRNA Levels of 
FOXA1, FOXD1, FOXM1 and UBE2C in NSCLC 
Patients
We further explored the prognosis of FOXA1, FOXD1, 
FOXM1 and UBE2C expression of patients with NSCLC. 
In Kaplan–Meier Plotter analysis, the correlations between 
the mRNA expression levels of the FOXA1, FOXD1, 
FOXM1 and UBE2C and the survival of patients with in 
LAC and LSCC was explored. Kaplan–Meier survival 
curve revealed that the expression levels of FOXA1and 
FOXD1 were not associated with the overall survival (OS), 
progression-free survival (FP) and post-progression sur-
vival (PPS) in all NSCLC patients (P > 0.05).
The significance of FOXM1 in the prognosis of NS-
CLC was explored through Kaplan–Meier Plotter analysis. 
The results revealed that high expression level of FOXM1 
was associated with shorter overall survival (OS) in NS-
CLC patients. It was founded that high expression level of 
FOXM1 was distinctly related to shorter overall survival 
(OS) (HR=1.7, p=0.0011) in NSCLC. (Figure 5A)
The prognostic value of UBE2C was explored through 
the Kaplan-Meier plotter. In figure 5B, UBE2C high 
mRNA expression was distinctly associated with shorter 
OS (HR=1.4, p=0.021) in NSCLC. (Figure 5 B)
5A: The prognostic values of mRNA expression level of 
FOXM1 in NSCLC patients
DOI: https://doi.org/10.30564/jams.v2i2.611
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5B: The prognostic values of mRNA expression level of 
UBE2C in NSCLC patients
Figure 5
4. Discussion
Lung cancer, mainly developing from bronchogenic cell, 
is not only the highest prevalence, but also  the cancer of 
supreme cancer-related mortality among all malignant 
tumor in the United States [16]. Despite great progress in 
diagnostic and treatment technology has been made in 
recent years, the 5-year overall survival rate of lung car-
cinoma remains less than 15% primarily contributing to 
resistance to conventional therapies, as well as distant me-
tastasis [17, 18] . It is rewarding to illustrate the oncogenesis 
of lung cancer and develop new prognostic biomarkers.
It is reported that FOX gene family plays an important 
role on regulating the growth, differentiation, apoptosis, 
proliferation, migration, invasion and angiogenesis of 
tumor cells [5]. ONCOMINE analysis revealed that, in the 
FOX gene family, FOXA1, FOXD1 and FOXM1 were 
significantly high expressed in NSCLC, implying their 
unique roles in NSCLC. The prognostic significance 
of FOXA1, FOXD1 and FOXM1 was further explored 
through Kaplan–Meier Plotter, revealing that FOXA1 and 
FOXD1 were not associated with prognosis in NSCLC, 
while FOXM1 was a vital prognostic biomarker for NS-
CLC patients especially for lung adenocarcinoma patients.
FOXA1 (Forkhead box A1) or HNF3α (hepatocyte nu-
clear factor 3α), is a major regulatory transcription factor 
regulating and controlling a range of tumors including 
breast, prostate and liver cancer.[19,20] It was found that 
FOXD1, up-regulated in different types of cancer includ-
ing prostate cancer, ovarian cancer and breast cancer, 
was associated with cancer proliferation and resistance 
to chemotherapy.[21-23] As a study reported that FOXD1 
was overexpressed in NSCLC and associated with poor 
prognosis.[24] However, in our current study, FOXA1 and 
FOXD1 were overexpressed in lung cancer. FOXA1 was 
especially high expressed in lung adenocarcinoma (LAC), 
while FOXD1 was in squamous cell lung carcinoma 
(LSCC). They didn’t vary from lung cancer stage and 
were not associated with prognosis of NSCLC.
FOXM1, which is essential for multi-organ cell prolif-
eration, differentiation and especially for cell apoptosis, 
was critical for the development and progression of a 
great deal of types of cancer.[25] ONCOMINE analysis re-
vealed that FOXM1 was overexpressed in lots of tumors 
including brain and CNS cancer, breast cancer, colorectal 
cancer, sarcoma and especially lung cancer. The results 
are in good agreement with the results of previous studies.
[24] In GEPIA analysis, FOXM1 was further demonstrated 
to overexpress in LAC and LSCC. Additionally, higher 
expression of FOXM1 was associated with later lung can-
cer stage. A study by Milewski et al. indicated overexpres-
sion of FOXM1 in LAC may associated with shorter OS 
or FP.[26] Similar results were indicated by Kaplan-Meier 
plotter survival analysis in the present study that a high 
level of FOXM1 overexpression was related to shorter 
survival in LC patients, especially in patients with LAC.
FOXM1 was positively associated with the expression 
of UBE2C, demonstrated by ONCOMINE co-expres-
sion analysis. The results were consistent with a study by 
Nicolau-Neto Palumbo et al., revealing that FOXM1 and 
UBE2C are co-expressed in esophageal squamous cell 
carcinoma and other types of cancer.[10,27]
UBE2C, as a transcription factor, plays an important 
role on the progression and prognosis of a variety of can-
cers including gastric carcinoma, rectal carcinoma and 
esophageal squamous cell carcinoma.[28-30] However, the 
signi cance of UBE2C in the prognosis of LC patients re-
mains deeply unknown. In the present study, ONCOMINE 
analysis revealed that UBE2C was highly expressed both 
in NSCLC patients and lung cancer cell lines. What is 
more, a high level of UBE2C expression was signi cant-
ly associated with later LC stage and shorter survival in 
LAC. The results were consistent with a study by Zhang 
et al. demonstrated that overexpression of UBE2C in NS-
CLC was correlated with poor prognosis. [31]
5. Conclusion
In summary, FOXA1, FOXD1 and FOXM1 were overex-
pressed in LC among FOX gene family.  FOXM1 is pos-
DOI: https://doi.org/10.30564/jams.v2i2.611
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itively associated with UBE2C, and they are distinctive 
biomarkers and predict shorter survival in LAC.
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